PBT2 from the Doherty Institute news site., page-4

"Dangerous antibiotic-resistant bacteria could soon by targeted with a drug initially developed to treat Alzheimer’s disease."
"Soon" sounds good. The normal cautions that it will be many years before the new drug gets to market is missing here. Considering an estimated 700,000 people die annually from antibiotic resistant bacteria, sooner rather than later is called for IMO. Considering phase 1 trials are completed and even safety data for PBT2 is there out to 2 years from the IMAGINE extension trial.